We are a fully integrated, commercial-stage biopharmaceutical company driving progress for people living with rare immune disorders. We listen to people whose challenges have been long overlooked, understand their needs, and develop solutions to their most urgent and critical health concerns. Our FDA-approved medication XOLREMDI® (mavorixafor) is commercially available in the U.S. in its first indication. We are evaluating mavorixafor in additional potential indications, and have an ongoing global, pivotal Phase 3 clinical trial for its use in chronic neutropenia. Our corporate headquarters is in Boston, Massachusetts.
Company Details
- Employees
- 111
- Founded
- -
- Address
- 61 N Beacon St, Boston,massachusetts 02134,united States
- Phone
- +1 857 529 8300
- in****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- x4pharma.com
- HQ
- Boston, Massachusetts
X4 Pharmaceuticals Questions
X4 Pharmaceuticals's helpline number is +1 857 529 8300
X4 Pharmaceuticals's website is x4pharma.com
X4 Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/x4-pharmaceuticals
X4 Pharmaceuticals has
111 employees.
View email and phone details for 111
employees at X4 Pharmaceuticals.
X4 Pharmaceuticals's industry is
Biotechnology Research
X4 Pharmaceuticals's top competitors are
Invivyd,
Kymera Therapeutics,
Sarepta Therapeutics,
Alnylam Pharmaceuticals,
Vertex Pharmaceuticals,
Xilio Therapeutics, Inc.,
Apellis Pharmaceuticals,
Agios Pharmaceuticals,
Beam Therapeutics,
Madrigal Pharmaceuticals.
X4 Pharmaceuticals's support email address is info@x4pharma.com
X4 Pharmaceuticals's categories are Biotechnology Research
X4 Pharmaceuticals's founding year is 2014
